




**Innovative Medicines Initiative** 

# Modeling ASD using human pluripotent stem cells

Ravi Jagasia F. Hoffmann-La-Roche AG Autism spectrum disorders represent a high unmet medical need with no current therapy available









IMI Stakeholder Forum – 21 May 2014 - Brussels

# Autism spectrum disorders is geneticaly complex limited pathophysiological understanding




### ASD genetically complex:

- Caused by genetic and environmental factors (hereditability estimated at 70%)
- Dozen of genes have been implicated. None account for >1%

### Unresolved:

- Is there Convergence? If so what and where?
  - Need for human relevant predictive models

Experimental tools needed to understand and treat ASD








## Dysfunction at the synapse is central to ASD










### Modelling ASD using human pluripotent stem cells






IMI Stakeholder Forum – 21 May 2014 - Brussels

# EU-AIMS achievements so far modelling ASD using human pluripotent stem cells





#### Generated several ASD models in a dish...

- ASD hIPSC lines
- Highly reproducible differentiation to functional neurons
- Identified molecular, synaptic and network deficits mimicking those in patients
- Promising tools for drug screening






## Summary and outlook – Opportunies and challenges



### **Open questions :**



- Can we identify using iPS cells from genetically different groups of ASD individuals the same deficits in the neurons and networks?
- Can we use this to guide the discovery of drug targets for specific groups of patients?
- How can we extend these results to a more general patient population?
  - Sampling from observational clinical trial





# Acknowledgments







*IMI Stakeholder Forum – 21 May 2014 - Brussels*